Latest Articles
-
What To Expect From Merck’s Q3?
Merck (NYSE: MRK) is scheduled to report its Q3 2021 results on Thursday, October 28. We expect the company to likely post revenue and earnings below the consensus estimates, as the spread of Covid-19 delta variant likely impacted the company&#...
-
Company Of The Day: Merck
What? Merck (NY SE: MRK) announced an agreement with Singapore to provide access to its experimental oral Covid-19 antiviral drug, molnupiravir. Australia has already ordered 300,000 courses of the drug, while Thailand, South Korea, Taiwan, a...
-
Here’s Why Merck Stock May Continue To Rise
[Updated: Oct 4, 2021] Merck Stock Rise The stock price of Merck (NYSE: MRK) surged 8% to levels of $81 on Friday, Oct 1, after the company announced that its Molnupiravir pill reduces the risk of hospitalization and death by 50% for patients ...
-
With Acceleron Acquisition Merck Stock Is Likely To See A Multiple Revision
[Updated: Oct 1, 2021] Merck To Acquire Acceleron Merck (NYSE: MRK) yesterday announced that it will acquire Acceleron Pharma – a biopharmaceutical company focused on rare diseases – for $11.5 billion funded in cash and debt. Accel...
-
Company Of The Day: Merck
What? The Wall Street Journal reports that Merck (NYSE:MRK) is looking to buy Acceleron Pharma, in a deal that could be announced as soon as this week. Why? A deal could bolster Merck’s rare diseases business. Acceleron’s most high...
-
Should You Buy Merck Stock At $72?
The stock price of Merck (NYSE: MRK) reached its 52-week high of around $82 in Sep 2020. It has since hovered in the range of $70-80 for the better part of the last year, and it currently trades at levels of around $72. We believe that MRK sto...
-
What’s Next For Merck Stock After A 5% Fall In A Week?
The stock price of Merck (NYSE: MRK) reached its all-time high of around $82 in Sep 2020. It has since hovered in the range of $70-80 for the better part of the last year, before a recent sell-off in pharmaceutical stocks resulted in MRK falli...
-
What’s Happening With Merck Stock?
The stock price of Merck (NYSE: MRK) has seen a 2.4% drop over the last five trading sessions led by a recent sell-off in large-cap pharmaceuticals stocks over the past week or so, with Johnson & Johnson, Pfizer, and Bristol Myers Squibb a...
-
Earnings Beat In Cards For Merck’s Q2?
Merck (NYSE: MRK) is scheduled to report its Q2 2021 results on Thursday, July 29. We expect the company to likely post revenue and earnings above the consensus estimates, led by continued expansion of Keytruda, and a recovery in the company...
-
Company Of The Day: Merck
What? The U.S. FDA approved a new version of Merck’s (NYSE:MRK) pneumococcal vaccine that prevents invasive disease caused by 15 strains of bacteria called Streptococcus pneumoniae. So What? Pneumococcal vaccines are lucrative and were t...
-
Does The Valuation Gap Between Merck Stock And Zoetis Make Sense?
Zoetis stock (NYSE:ZTS) has risen 2x from levels of $92 that it was at on March 23, 2020, when broader markets made a bottom, to levels of $184 now, while Merck’s stock (NYSE:MRK) has underperformed and gained only 26% of its value. Looking ...
-
Forecast Of The Day: Merck’s Oncology Drug Sales
What? Trefis expects Merck (NYSE:MRK) Oncology drug sales to grow from levels of around $16 billion in 2020 to $19 billion in 2021 and $22 billion in 2022. Why? We expect growth to come on the back of higher sales of Merck’s immensely p...
-
What’s Next For Merck Stock After A 5% Drop Following Q1 Miss?
[Updated: 4/30/2021] Merck Stock Decline The stock price of Merck (NYSE:MRK) has seen a 5.5% drop over the last five trading days, after the company announced Q1 results that came in below the street estimates. Merck’s Q1 revenue of $12.1 billi...
-
Earnings Beat In Cards For Merck’s Q1?
Merck (NYSE: MRK) is scheduled to report its Q1 2021 results on Thursday, April 29. We expect the company to likely post revenue and earnings above the consensus estimates, led by continued expansion of Keytruda, and a recovery in the companyR...
-
Merck Stock Remains Significantly Undervalued At $77
Merck (NYSE: MRK) looks very attractive at current levels of $77, as it is up only 17% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This marks a significant underperformance compar...
